Marshall Wace, LLP Astria Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
A detailed history of Marshall Wace, LLP transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 70,241 shares of ATXS stock, worth $639,193. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70,241
Previous 14,300
391.2%
Holding current value
$639,193
Previous $109,000
806.42%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ATXS
# of Institutions
122Shares Held
48.8MCall Options Held
3.59MPut Options Held
483K-
Perceptive Advisors LLC New York, NY6.49MShares$59 Million1.91% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.28MShares$48 Million7.82% of portfolio
-
Vr Adviser, LLC New York, NY3.61MShares$32.8 Million4.36% of portfolio
-
Black Rock Inc. New York, NY3.59MShares$32.6 Million0.0% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$32.3 Million7.97% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $138M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...